Amiloxate

From Wikipedia, the free encyclopedia
Amiloxate
Amiloxate.svg
Names
Preferred IUPAC name
3-Methylbutyl (2E)-3-(4-methoxyphenyl)prop-2-enoate
Other names
Isopentyl 4-methoxycinnamate; Isoamyl p-methoxycinnamate
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.068.798 Edit this at Wikidata
UNII
  • InChI=1S/C15H20O3/c1-12(2)10-11-18-15(16)9-6-13-4-7-14(17-3)8-5-13/h4-9,12H,10-11H2,1-3H3/b9-6+
    Key: UBNYRXMKIIGMKK-RMKNXTFCSA-N
  • InChI=1/C15H20O3/c1-12(2)10-11-18-15(16)9-6-13-4-7-14(17-3)8-5-13/h4-9,12H,10-11H2,1-3H3/b9-6+
    Key: UBNYRXMKIIGMKK-RMKNXTFCBL
  • CC(C)CCOC(=O)/C=C/C1=CC=C(C=C1)OC
Properties
C15H20O3
Molar mass 248.322 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Amiloxate is a sunscreening agent. It is approved for use in the European Union and is undergoing regulatory evaluation in the United States.[1][2]

See also[]

References[]

  1. ^ Brian Palmer (23 April 2014). "Burned by Bureaucracy: Why is the FDA stalling on newer and better sunscreens?". Slate.com.
  2. ^ Britt Erickson (May 12, 2014). "Sunscreen Delays". Chemical & Engineering News. 92 (19): 27. doi:10.1021/cen-09219-govpol2.


Retrieved from ""